Back to Search
Start Over
Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults
- Source :
- Antimicrobial agents and chemotherapy. 66(10)
- Publication Year :
- 2022
-
Abstract
- Ensitrelvir is a novel selective inhibitor of the 3C-like protease of SARS-CoV-2, which is essential for viral replication. This phase 1 study of ensitrelvir assessed its safety, tolerability, and pharmacokinetics of single (part 1, n = 50) and multiple (part 2, n = 33) ascending oral doses.
- Subjects :
- Pharmacology
Adult
Indazoles
Dose-Response Relationship, Drug
SARS-CoV-2
Triazines
Midazolam
Administration, Oral
Triazoles
Antiviral Agents
Healthy Volunteers
COVID-19 Drug Treatment
Infectious Diseases
Double-Blind Method
Area Under Curve
Humans
Cytochrome P-450 CYP3A
Pharmacology (medical)
Protease Inhibitors
Enzyme Inhibitors
Peptide Hydrolases
Subjects
Details
- ISSN :
- 10986596
- Volume :
- 66
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Antimicrobial agents and chemotherapy
- Accession number :
- edsair.doi.dedup.....f77977e017415c5bdcd207c02c122c61